Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337876 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL337914 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL334606 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL16539029 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL336557 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL4821245 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL17633906 | 1.00 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL18378739 | 0.99 | KMT2A (0.46) | KMT2ANOD1POLBPLA2G2CMEN1 | |
| SCHEMBL24819248 | 0.93 | KMT2A (0.44) | KMT2ANOD1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL20467657 | 0.93 | KMT2A (0.44) | KMT2ANOD1POLBL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1840134-B1 | GLP-1 derivatives | NOVO NORDISK AS (DK) | 2016-04-13 | — | — | EP | disclosed |
| US-8097698-B2 | Derivatives of GLP-1 analogs | NOVO NORDISK A/S (DK) | 2012-01-17 | — | — | US | disclosed |
| US-20110053839-A1 | GLP-1 Derivatives II | NOVO NORDISK A/S (DK) | 2011-03-03 | — | — | US | disclosed |
| EP-1056775-B1 | GLP-1 DERIVATIVES OF GLP-1 AND EXENDIN WITH PROTRACTED PROFILE OF ACTION | NOVO NORDISK AS (DK) | 2010-04-28 | — | — | EP | disclosed |
| US-20090176700-A1 | Derivatives Of GLP-1 Analogs | NOVO NORDISK A/S (DK) | 2009-07-09 | — | — | US | disclosed |
| US-7411039-B2 | GLP-2 compounds, formulations, and uses thereof | NOVO NORDISK A/S (DK) | 2008-08-12 | — | — | US | disclosed |
| US-20080103097-A1 | GLP-1 derivatives II | NOVO NORDISK A/S (DK) | 2008-05-01 | — | — | US | disclosed |
| EP-1840134-A2 | GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2007-10-03 | — | — | EP | disclosed |
| US-20060199763-A1 | Derivatives of GLP-1 analogs | KNUDSEN LISELOTTE B | 2006-09-07 | — | — | US | disclosed |
| WO-2005082404-A2 | GLP-2 DERIVATIVES MODIFIED BY LIPOPHILIC SUBSTITUENTS | NOVO NORDISK A/S (DK) | 2005-09-09 | — | — | WO | disclosed |
| EP-1554308-A2 | GLUCAGON-LIKE PEPTIDE - 2 VARIANTS | NOVO NORDISK A/S (DK) | 2005-07-20 | — | — | EP | disclosed |
| US-20040122210-A1 | GLP-2 compounds, formulations, and uses thereof | NOVO NORDISK A/S (DK) | 2004-06-24 | — | — | US | disclosed |
| WO-2004035624-A2 | GLUCAGON - LIKE PEPTIDE - 2 VARIANTS | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | WO | disclosed |
| EP-1061946-B1 | GLP-1 DERIVATIVES WITH HELIX-CONTENT EXCEEDING 25 %, FORMING PARTIALLY STRUCTURED MICELLAR-LIKE AGGREGATES | NOVO NORDISK AS (DK) | 2004-04-28 | — | — | EP | disclosed |
| US-6458924-B2 | POLYPEPTIDE DRUG; ANTIDIABETIC AGENT; Liraglutide | NOVO NORDISK A/S (DK) | 2002-10-01 | — | — | US | disclosed |
| US-20010011071-A1 | DERIVATIVES OF GLP-1 ANALOGS | KNUDSEN LISELOTTE BJERRE (DK) | 2001-08-02 | — | — | US | disclosed |
| US-6268343-B1 | HUMAN GLUCAGON-LIKE PEPTIDE-1; MORE PROTRACTED PROFILE OF ACTION THAN THE PARENT PEPTIDES; TREATING DIABETES AND OBESITY; Liraglutide | NOVO NORDISK A/S (DK) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199763-A1 | Derivatives of GLP-1 analogs | GLP1R, GIPR, IAPP | KMT2A 4314/4885NOD1 707/4885POLB 4707/4885 |
| US-20090176700-A1 | Derivatives Of GLP-1 Analogs | GLP1R, GIPR, IAPP | KMT2A 4314/4885NOD1 707/4885POLB 4707/4885 |
| US-20040122210-A1 | GLP-2 compounds, formulations, and uses thereof | GLP1R, GIPR, IAPP | KMT2A 3028/4885NOD1 1284/4885POLB 1721/4885 |
| US-20010011071-A1 | DERIVATIVES OF GLP-1 ANALOGS | GLP1R, GIPR, IAPP | KMT2A 4314/4885NOD1 707/4885POLB 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.